Skip to main content
. Author manuscript; available in PMC: 2021 Apr 17.
Published in final edited form as: Lab Invest. 2020 Oct 17;101(4):503–512. doi: 10.1038/s41374-020-00498-x

Table 1.

Significantly enriched miRNA seed variants in the comparison of patient cohort with gnomAD NFE population.

miRNA Chr Start End Ref Alt dbSNP150 AF_Patient1 AF_gnomAD NFE1 pVal2 FDR3
hsa-mir-4472-2-5p 12 116866112 116866114 CA - rs202127912 0.23 1.60E-02 2.6E-54 1.5E-51
hsa-mir-8078–3p 18 112284 112285 G C 0 0.17 3.90E-02 2.2E-16 6.1E-15
hsa-mir-8078–3p 18 112286 112287 C A rs775697263 0.15 3.50E-02 4.3E-16 1.2E-14
hsa-mir-8078–3p 18 112281 112282 C A 0 0.04 1.00E-03 5.4E-13 1.2E-11
hsa-mir-1273a-3p 8 101036233 101036234 G A rs932668866 0.01 1.34E-04 1.2E-04 1.5E-03
hsa-mir-6859-1-3p 1 17384 17385 G A rs201535981 0.25 1.60E-01 6.1E-04 6.8E-03
hsa-mir-1273d-5p 1 10287790 10287791 A G 0 0.01 6.74E-05 1.6E-03 1.6E-02
hsa-mir-302c-3p 4 113569539 113569543 ACTT - rs199971565 0.06 3.00E-02 5.1E-03 4.4E-02
1

Allele Frequency of the patient and gnomAD NFE group, respectively

2

Raw p-value from Fisher’s Exact test

3

Benjamini-Hochberg adjusted p-value